Cargando…

Real-world outcomes of immunotherapy with or without chemotherapy in first-line treatment of advanced non-small cell lung cancer

BACKGROUND: Immunotherapy alone (mono-IT) or combined with chemotherapy (chemo-IT) has recently become the cornerstone of first-line treatment for advanced non-small cell lung cancer (NSCLC) patients. Here, real-world outcomes of first-line mono-IT and chemo-IT of advanced NSCLC treated within routi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pelicon, Veronika, Cufer, Tanja, Knez, Lea
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10316645/ https://www.ncbi.nlm.nih.gov/pubmed/37404771 http://dx.doi.org/10.3389/fonc.2023.1182748

Ejemplares similares

Real-World Efficacy and Safety of Anlotinib With and Without Immunotherapy in Advanced Non-Small Cell Lung Cancer
por: Xiong, Qi, et al.
Publicado: (2021)

Real World Evidence on Second-Line Palliative Chemotherapy in Advanced Pancreatic Cancer
por: Gränsmark, Emma, et al.
Publicado: (2020)

Oral treatment with etoposide in small cell lung cancer – dilemmas and solutions
por: Rezonja, Renata, et al.
Publicado: (2013)

Indirect comparison between immunotherapy alone and immunotherapy plus chemotherapy as first-line treatment for advanced non-small cell lung cancer: a systematic review
por: Li, Lingling, et al.
Publicado: (2020)

Efficacy and safety evaluation of neoadjuvant immunotherapy plus chemotherapy for resectable non–small cell lung cancer in real world
por: Fang, Min, et al.
Publicado: (2023)

PD-1 inhibitor versus bevacizumab in combination with platinum-based chemotherapy for first-line treatment of advanced lung adenocarcinoma: A retrospective-real world study
por: Huang, Zhe, et al.
Publicado: (2022)

The efficacy and safety of anlotinib combined with platinum-etoposide chemotherapy as first-line treatment for extensive-stage small cell lung cancer: A Chinese multicenter real-world study
por: Zheng, Hao-Ran, et al.
Publicado: (2022)

First Line and Second Line Chemotherapy in Advanced Cholangiocarcinoma and Impact of Dose Reduction of Chemotherapy: A Retrospective Analysis
por: Möhring, Christian, et al.
Publicado: (2021)

Outcome of small cell lung cancer (SCLC) patients with brain metastases in a routine clinical setting
por: Lekic, Mirko, et al.
Publicado: (2012)

Immunotherapy combined with rh-endostatin improved clinical outcomes over immunotherapy plus chemotherapy for second-line treatment of advanced NSCLC
por: Huang, Hongxiang, et al.
Publicado: (2023)

A Changing of the Guard: Immune Checkpoint Inhibitors With and Without Chemotherapy as First Line Treatment for Metastatic Non-small Cell Lung Cancer
por: Pacheco, Jose M., et al.
Publicado: (2019)

Efficacy of immunotherapy in KRAS-mutant advanced NSCLC: A real-world study in a Chinese population
por: Peng, Lixiu, et al.
Publicado: (2023)

Real world evidence of Lenvatinib + anti PD-1 as an advanced line for metastatic melanoma
por: Stoff, Ronen, et al.
Publicado: (2023)

Real-World Therapy Management and Outcomes of First-Line Axitinib Plus Pembrolizumab in Patients With Advanced Renal Cell Carcinoma in the United States
por: Zakharia, Yousef, et al.
Publicado: (2022)

Immunotherapy-related adverse events in real-world patients with advanced non-small cell lung cancer on chemoimmunotherapy: a Spinnaker study sub-analysis
por: Anpalakhan, Shobana, et al.
Publicado: (2023)

Real-world evidence on first- and second-line palliative chemotherapy in advanced pancreatic cancer
por: Blomstrand, Hakon, et al.
Publicado: (2021)

S-1 Maintenance Therapy After First-Line Treatment With Nab-Paclitaxel Plus S-1 for Advanced Pancreatic Adenocarcinoma: A Real-World Study
por: Shi, Yan, et al.
Publicado: (2022)

Cost-Utility Analysis of Camrelizumab Plus Chemotherapy Versus Chemotherapy Alone as a First-Line Treatment for Advanced Nonsquamous Non-Small Cell Lung Cancer in China
por: Chen, Ting, et al.
Publicado: (2022)

Comparative Efficacy and Safety of Immunotherapy Alone and in Combination With Chemotherapy for Advanced Non-small Cell Lung Cancer
por: Wang, Xue, et al.
Publicado: (2021)

Cost-Effectiveness Analysis of Nivolumab Plus Ipilimumab vs. Chemotherapy as First-Line Therapy in Advanced Non-Small Cell Lung Cancer
por: Hu, Huabin, et al.
Publicado: (2020)

First‐line immunotherapy or angiogenesis inhibitor combined with chemotherapy for advanced non‐small cell lung cancer with EGFR exon 20 insertions: Real‐world evidence from China
por: Yang, Guangjian, et al.
Publicado: (2022)

Real-World First-Line Treatment Patterns and Outcomes in Hormone Receptor-Positive Advanced Breast Cancer Patients: A Multicenter, Retrospective Study in China
por: Chen, Zhanhong, et al.
Publicado: (2022)

Cost-effectiveness of first-line immunotherapy combinations with or without chemotherapy for advanced non–small cell lung cancer: a modelling approach
por: Hui, Wen, et al.
Publicado: (2023)

Real-world outcomes of patients with advanced intrahepatic cholangiocarcinoma treated with programmed cell death protein-1-targeted immunotherapy
por: Deng, Min, et al.
Publicado: (2022)

Occult hepatitis B in patients with cancer during immunotherapy with or without chemotherapy: A real-life retrospective single-center cohort study
por: Lasagna, Angioletta, et al.
Publicado: (2023)

Effect of depression disorder on the efficacy and quality of life of first-line chemotherapy combined with immunotherapy in oncogene-driver negative NSCLC patients
por: Li, Wen, et al.
Publicado: (2022)

First-line programmed death-1 inhibitor treatment for locoregionally advanced or metastatic cutaneous squamous cell carcinoma – A real-world experience from Israel
por: Averbuch, Itamar, et al.
Publicado: (2023)

Radiotherapy or chemotherapy: a real-world study of the first-time relapsed and refractory primary central nervous system lymphoma
por: Yang, Yu, et al.
Publicado: (2023)

A Network Meta-Analysis of Cancer Immunotherapies Versus Chemotherapy for First-Line Treatment of Patients With Non-Small Cell Lung Cancer and High Programmed Death-Ligand 1 Expression
por: Herbst, Roy, et al.
Publicado: (2021)

Cost-Effectiveness of Nivolumab Plus Ipilimumab With and Without Chemotherapy for Advanced Non-Small Cell Lung Cancer
por: Yang, Szu-Chun, et al.
Publicado: (2021)

Prognostic value of tumor mutation burden in patients with advanced gastric cancer receiving first-line chemotherapy
por: Duan, Xiao-Peng, et al.
Publicado: (2023)

Immune checkpoint inhibitors alone or in combination with chemotherapy for treatment of advanced non-small cell lung cancer after first-line platinum-based chemotherapy: A propensity score matching analysis
por: Qiu, Lupeng, et al.
Publicado: (2022)

Efficacy of apatinib 250 mg combined with chemotherapy in patients with pretreated advanced breast cancer in a real-world setting
por: Zhang, Ruyan, et al.
Publicado: (2023)

Efficacy of Combination Chemo-Immunotherapy as a First-Line Treatment for Advanced Non-Small-Cell Lung Cancer Patients With HER2 Alterations: A Case Series
por: Zhao, Shuang, et al.
Publicado: (2021)

Oligorecurrence Non–small Cell Lung Cancer After Failure of First-Line Chemotherapy: Computed Tomography–Guided (125)I Seed Implantation vs. Second-Line Chemotherapy
por: Wang, Hao, et al.
Publicado: (2020)

Consideration of Surrogate Endpoints for Overall Survival Associated With First-Line Immunotherapy in Extensive-Stage Small Cell Lung Cancer
por: Zhang, Shuang, et al.
Publicado: (2021)

Real-world performance of blood-based proteomic profiling in first-line immunotherapy treatment in advanced stage non-small cell lung cancer
por: Rich, Patricia, et al.
Publicado: (2021)

The Real-world Therapeutic Analysis of First-line Immunotherapy in Chinese Patients with Drive Gene Positive for Advanced Non-Small Cell Lung Cancer
por: Liu, Lei, et al.
Publicado: (2023)

Nationwide Survival Benefit after Implementation of First-Line Immunotherapy for Patients with Advanced NSCLC—Real World Efficacy
por: Mouritzen, Mette T., et al.
Publicado: (2021)

Economic evaluation of first-line sugemalimab plus chemotherapy for metastatic non-small cell lung cancer in China
por: Wang, Hao, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_huksgevkfse8ioahe33mb0al2t